Alpha-Cyclodextrin Flurane Complex for Aqueous Anesthetic Formulation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Flurane anesthetics are typically administered via inhalation, which limits their administration route and has challenges due to their low boiling point and high vapor level, and existing formulations do not allow for alternative routes like oral or intravenous administration.

Innovation Solution

A complex formed between α-cyclodextrin and flurane, with a flurane content of at least 3% by weight, where the flurane acts as a guest molecule within the cyclodextrin cavity, enabling the formulation of an aqueous solution suitable for oral or intravenous administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If flurane is administered via inhalation, then anesthetic efficacy is achieved, but administration route is limited and requires specialized equipment

Engineering Contradiction:
Improveadministration routeVSAvoidvaporizer and respiratory equipment
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent uses cyclodextrin as an intermediary carrier substance that binds to flurane molecules, enabling the anesthetic to be administered via oral or intravenous routes instead of requiring inhalation equipment. The cyclodextrin-flurane complex acts as the mediator that allows alternative administration routes while maintaining anesthetic efficacy.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If flurane content in formulation is increased, then anesthetic efficacy is improved, but flurane volatility and instability increase

Engineering Contradiction:
Improveanesthetic efficacyVSAvoidflurane stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent embeds flurane molecules within the cavity structure of cyclodextrin rings, creating a nested complex where the flurane is housed inside the cyclodextrin cavity. This nesting structure stabilizes the flurane by preventing its volatility and decomposition, while still allowing sufficient flurane content (3-15% by weight) to maintain anesthetic efficacy.

Inventive Principle:
Principle #7Nested doll (Nesting)

3Adaptability or versatility

If flurane is formulated as aqueous solution, then alternative administration routes are enabled, but flurane solubility is reduced

Engineering Contradiction:
Improveadministration routeVSAvoidflurane solubility
Core Design Contradiction:
Adaptability or versatilityVSQuantity of substance

Solution Approach 1:

Cyclodextrin serves as a solubility-enhancing intermediary that allows flurane to be dissolved in aqueous solutions. The cyclodextrin-flurane complex increases the apparent solubility of flurane in water, enabling formulation concentrations of 3-15% by weight, which would otherwise be impossible due to flurane's inherent low water solubility.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the formulation of flurane anesthetics with high flurane content, providing a stable aqueous solution that can be administered orally or intravenously, overcoming the limitations of inhalation administration and maintaining anesthetic efficacy.

Implementation Method 1

The fluranes enter this cavity as a guest molecule, such that a complex of the extremely lipophilic fluranes which can be formulated as an aqueous solution is obtained

Methodology Applied
Scientific EffectInclusion complex formation: Absorption (physical)

Data Source

PatentUS9125953B2Halogenated ether complex
Publication Date: 2015.09.08 SAPIOTEC

AI summary

The invention relates to a complex made of α-cyclodextrin and a halogenated ether, characterized by a content of the halogenated ether of at least 3 wt % of the total weight of the complex.